UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 11, 2022 idxx-20220511_g1.jpg

| | Delaware | Exact name of registrant 000-1 | • | 01-0393723 | |
|-----------------------------------|---|---|---|--|------|
| | (State or other jurisdiction of incorporation) | (Commission File Number) | | (IRS Employer Identification No.) | |
| | One IDEXX Drive (Address of prin | Westbrook, acipal executive offices) | Maine | 04092 (ZIP Code) | |
| | (Forme | Not App er name or former addres | blicable s, if changed since | last report) | |
| | | ded to simultaneously satisfy t | the filing obligation of th | e registrant under any of the following provisions (<u>see</u> Gene | eral |
| Theck the appropostruction A.2. b | | , , | 0 0 | e registrant under any of the following provisions (<u>see</u> Gene | eral |
| nstruction A.2. b | elow): | 425 under the Securities Act | (17 OFR 230.425) | e registrant under any of the following provisions (<u>see</u> Gene | eral |
| nstruction Å.2. b | elow): Written communications pursuant to Rule | 425 under the Securities Act 2 under the Exchange Act (1 | (17 CFR 230.425) 7 CFR 240.14a-12) | | eral |
| nstruction A.2. b | elow): Written communications pursuant to Rule Soliciting material pursuant to Rule 14a-1 | 425 under the Securities Act 12 under the Exchange Act (1' suant to Rule 14d-2(b) under t | (17 CFR 230.425) 7 CFR 240.14a-12) the Exchange Act (17 C | FR 240.14d-2(b)) | eral |
| nstruction A.2. b | elow): Written communications pursuant to Rule Soliciting material pursuant to Rule 14a-1 Pre-commencement communications pursuant to Rule 14a-1 | 425 under the Securities Act 12 under the Exchange Act (1' suant to Rule 14d-2(b) under t | (17 OFR 230.425) 7 OFR 240.14a-12) the Exchange Act (17 O | FR 240.14d-2(b)) FR 240.13e-4(c)) | eral |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box

D7. Submission of Matters to a Vote of Security Holders.

On May 11, 2022, IDEXX Laboratories, Inc. (the "Company") held its 2022 annual meeting of shareholders (the "Annual Meeting"). At the Annual Meeting, shareholders considered and voted on the following proposals, each of which is described in more detail in the Company's proxy statement dated March 31, 2022, (the "Proxy Statement"): (1) the election of Jonathan W. Ayers, Stuart Essig, PhD, Jonathan J. Mazelsky and M. Anne Szostak each as Class III directors, for terms expiring at the 2025 annual meeting of shareholders; (2) the ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered accounting firm for the current fiscal year; and (3) the approval, on an advisory basis, of the compensation of the Company's named executive officers as presented in the Proxy Statement delivered to shareholders in connection with the Annual Meeting.

The voting results at the Annual Meeting with respect to each of the matters described above, were as follows:

Proposal One: Election of Directors

| Nominees | For | Against | Abstain | Broker Non-Votes |
|----------------------|------------|-----------|---------|-------------------------|
| Jonathan W. Ayers | 65,592,478 | 4,630,197 | 94,139 | 5,573,815 |
| Stuart Essig, PhD | 66,053,066 | 4,014,895 | 248,853 | 5,573,815 |
| Jonathan J. Mazelsky | 69,939,751 | 280,878 | 96,185 | 5,573,815 |
| M. Anne Szostak | 66,212,563 | 4,004,497 | 99,754 | 5,573,815 |

| Proposal Two: | roposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm | | |
|------------------|---|--|--|
| For | 71,735,760 | | |
| Against | 4,064,423 | | |
| Abstain | 90,446 | | |
| Broker Non-Votes | N/A | | |

| Proposal Three: | Advisory Vote to Approve Executive Compensation | |
|------------------|---|------------|
| For | | 66,515,843 |
| Against | | 3,643,026 |
| Abstain | | 157,945 |
| Broker Non-Votes | | 5,573,815 |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IDEXX LABORATORIES, INC.

Date: May 13, 2022 By: /s/ Sharon E. Underberg

Sharon E. Underberg

Executive Vice President, General Counsel and Corporate Secretary